Scientific Advice: ECDC Reviews

New Swedish Registry study confirms increased risk of narcolepsy in children and adolescents after vaccination with Pandemrix

System Account — Fri, 03 May 2013 09:48:18 GMT

(conducted by the Swedish Medical Product Agency in collaboration with the Karolinska Institute)

This observational cohort study utilizing electronic health care records covering 5.8 million Swedes confirmed an increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents (<20 years).

Association of childhood narcolepsy and cataplexy and receipt of a pandemic influenza vaccine in Finland in 2009-10 – First papers in a peer review journal

System Account — Fri, 30 Mar 2012 09:56:31 GMT

Updated guidance on novel coronavirus by WHO: surveillance, applied epidemiological studies and clinical guidance

System Account — Wed, 27 Mar 2013 09:22:33 GMT

Association of receipt of Pandemrix™ and narcolepsy in children and adolescents in the UK (England)

System Account — Mon, 18 Mar 2013 12:30:17 GMT

WHO Recommendation on influenza virus vaccines for the Northern Hemisphere 2013-2014 season

System Account — Fri, 15 Mar 2013 09:11:26 GMT

On 21 February 2013, WHO issued its recommendation for the composition of influenza vaccines for the 2013-2014 influenza season in the Northern Hemisphere.

Large measles outbreak in Geneva, Switzerland, January to August 2011: descriptive epidemiology and demonstration of quarantine effectiveness.

System Account — Mon, 11 Feb 2013 09:47:53 GMT

Pertactin-Negative Variants of Bordetella pertussis in the United States

System Account — Mon, 11 Feb 2013 09:44:49 GMT

Estimating age specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.

System Account — Fri, 08 Feb 2013 13:33:54 GMT

Seasonal influenza vaccine produced using recombinant technology approved for use in North America

System Account — Fri, 08 Feb 2013 09:02:34 GMT

New tuberculosis drug bedaquiline approved by U.S. Food and Drug Administration

System Account — Fri, 11 Jan 2013 16:05:09 GMT

On 28 December 2012, the U.S. Food and Drug Administration approved bedaquiline, a new diarylquinoline antimycobacterial drug, as part of combination therapy to treat adults with multi-drug resistant tuberculosis (MDR-TB) when other alternatives are not available.

Epidemiologic framework for assessing the severity of influenza epidemics and pandemics

System Account — Fri, 11 Jan 2013 12:35:04 GMT